[1]Shen Q, Liu S, Chen Y, et al. Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation[J]. J Hematol Oncol, 2013, 6:64.
[2]Deng J, He M, Chen L, et al. The loss of miR-26a-mediated post-transcriptional regulation of cyclin E2 in pancreatic cancer cell proliferation and decreased patient survival[J]. PLoS One, 2013, 8(10):e76450.
[3]Molli PR, Pradhan MB, Advani SH, et al. RhoA: a therapeutic target for chronic myeloid leukemia[J]. Mol Cancer, 2012, 11:16.
[4]Wang J, Liu XH, Yang ZJ, et al. The effect of ROCK-1 activity change on the adhesive and invasive ability of Y79 retinoblastoma cells[J]. BMC Cancer, 2014, 14(1):89.
[5]Li YW, Wang JX, Yin X, et al. Decreased expression of GATA2 promoted proliferation, migration and invasion of HepG2 in vitro and correlated with poor prognosis of hepatocellular carcinoma[J]. PLoS One, 2014, 9(1):e87505.
[6]Huang F, Lin C, Shi YH, et al. MicroRNA-101 inhibits cell proliferation, invasion, and promotes apoptosis by regulating cyclooxygenase-2 in HeLa cervical carcinoma cells[J]. Asian Pac J Cancer Prev, 2013, 14(10):5915-5920.
[7]Li YY, Li G, Mi L, et al. Expression of integrin-linked kinase in fibroblasts of scar induced by cobalt chloride and its effect on cell proliferation[J]. Zhonghua Shao Shang Za Zhi, 2013, 29(3):300-303.
[8]Deng M, Liu JF, Gu YX, et al. miR-216b suppresses cell proliferation and invasion by targeting PKC alpha in nasopharyngeal carcinoma cells[J]. Zhonghua Zhong Liu Za Zhi, 2013, 35(9):645-650.
[9]Reed K, Hembruff SL, Laberge ML, et al. Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells[J]. Epigenetics, 2008,3(5):270-280.
[10]Sekeres MA. The euphoria of hypomethylating agents in MDS and AML: Is it justified[J]? Best Pract Res Clin Haematol, 2013, 26(3):275-278.
[11]Pierdomenico F, Esteves S, Almeida A. Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS[J]. Ann Hematol, 2013, 92(9):1201-1206.
[12]Wang LQ, Kwong YL, Wong KF, et al. Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia[J]. J Transl Med, 2014, 12(1):52.
[13]Fandy TE, Jiemjit A, Thakar M, et al. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes[J]. Clin Cancer Res, 2014, 20(5):1249-1258.
[14]Zucchetto A, Caldana C, Benedetti D, et al. CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism[J]. Blood, 2013, 122(19):3317-3321.
[15]Nishioka C, Ikezoe T, Yang J, et al. Downregulation of miR-217 correlates with resistance of Ph(t) leukemia cells to ABL tyrosine kinase inhibitors[J]. Cancer Sci, 2014, 105(3):297-307.
[16]Della Peruta M, Martinelli G, Moratti E, et al. Protein tyrosine phosphatase receptor type is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia[J]. Cancer Res, 2010, 70(21):8896-8906.
[17]San Jose-Eneriz E, Agirre X, Jimenez-Velasco A, et al. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia[J]. Eur J Cancer, 2009,45(10):1877-1889.
[18]Ortmann CA, Burchert A, Holzle K, et al. Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region[J]. Nucleic Acids Res, 2005,33(21):6895-6905.
[19]Hrebackova J, Hrabeta J, Eckschlager T. Valproic acid in the complex therapy of malignant tumors[J]. Curr Drug Targets, 2010, 11(3):361-379.
[20]Babashah S, Sadeghizadeh M, Hajifathali A, et al. Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD34+ CML stem/progenitor cells[J]. Int J Cancer, 2013, 133(3):579-589.
[21]Li Y, Wang H, Tao K, et al. miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein[J]. Exp Cell Res, 2013, 319(8):1094-1101. |